ABSTRACT
INTRODUCTION: The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored. OBJECTIVE: Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted. METHODS: Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent. RESULTS: This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage. CONCLUSIONS: Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment.
Subject(s)
Amides/therapeutic use , Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Pyrazines/therapeutic use , Animals , COVID-19/virology , Humans , SARS-CoV-2/drug effects , SARS-CoV-2/isolation & purification , Treatment OutcomeABSTRACT
There is a strong consensus globally that a COVID-19 vaccine is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 - the virus that causes COVID-19 - currently undergoing early phase human trials. We also consider the many challenges of developing and deploying a new vaccine on a global scale, and recommend caution with respect to our expectations of the timeline that may be ahead.